LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1
Biochemical Pharmacology · 2026-01 · 243 · 117553
DOI: 10.1016/j.bcp.2025.117553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-01. Verfasst von Sensheng Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, B7-H1 Antigen, Histones, Lactate Dehydrogenase 5. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Jiangsu Province Natural Science Foundation, Nanjing Medical University.
Abstract (Originalsprache)
Metabolic reprogramming, characterized by hyperactive glycolysis, is a hallmark of bladder cancer (BCa) progression. Here, we identify lactate dehydrogenase A (LDHA) as a central metabolic node coupling glycolytic flux to epigenetic regulation of the immune checkpoint molecule PD-L1. Transcriptomic and survival analyses reveal that dysregulated glycolytic enzymes, particularly LDHA, correlate with poor prognosis and immunotherapy response in BCa patients. Mechanistically, LDHA-driven lactate production induces histone H4K5 lactylation (H4K5la), facilitated by the acetyltransferase EP300, which directly activates PD-L1 transcription. Depletion of LDHA or EP300 reduces H4K5la levels and suppresses PD-L1 expression. Critically, EP300 knockdown reverses PD-L1 upregulation induced by LDHA overexpression, establishing a causal LDHA-EP300-H4K5la-PD-L1 axis that drives immune evasion. Furthermore, RNA immunoprecipitation and luciferase reporter assays suggest that m6A RNA modification may potentiate LDHA overexpression. Collectively, this work unveils a dual-layered mechanism-metabolic lactate flux and histone lactylation that orchestrates immune evasion in BCa, proposing LDHA and EP300 as actionable targets to restore antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.
- Department of Urology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China; Department of Urology, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
- Department of Urology, Xuzhou Cancer Hospital Affiliated to Jiangsu University, Xuzhou Cancer Hospital, Xuzhou, China.
- Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: kaili98@njmu.edu.cn.
- Department of Hematology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China. Electronic address: xia816yuan@163.com.
- Department of Urology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China; Department of Urology, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China. Elec…
Förderung
- Jiangsu Province Natural Science Foundation
- Nanjing Medical University
Zitieren
APA
Tang, S., Liu, Y., Jin, B., Zhang, T., Wang, X., Zhao, J., Xu, Z., Zhao, W., Bian, H., Li, K., Xia, Y., Wang, H., & Guo, M. (2026). LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1. Biochemical Pharmacology, 243, 117553. https://doi.org/10.1016/j.bcp.2025.117553
Vancouver
Tang S, Liu Y, Jin B, Zhang T, Wang X, Zhao J, et al. LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1. Biochemical Pharmacology. 2026;243:117553. doi:10.1016/j.bcp.2025.117553
BibTeX
@article{Tang2026,
author = {Tang, Sensheng and Liu, Yu and Jin, Bo and Zhang, Tianyang and Wang, Xingbo and Zhao, Jie and Xu, Zhibin and Zhao, Wenchao and Bian, Hao and Li, Kai and Xia, Yuan and Wang, Hui and Guo, Maomao},
title = {LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {243},
pages = {117553},
doi = {10.1016/j.bcp.2025.117553}
}
EUVIMED